Viacyte to Present Update On VC-01™ Combination Product Development at 2013 Stem Cell Meeting on The Mesa

San Diego, California, October 10, 2013 – ViaCyte, Inc. announced today that an update on the Company’s progress toward a transformative stem cell-derived cell therapy for the treatment of type 1 diabetes will be presented at the 3rd Annual Regen Med Partnering Forum, part of the 2013 Stem Cell Meeting on the Mesa to be held October 14-16 in La Jolla, California. The presentation will be given by Eugene Brandon, Ph.D., Director of Strategic Relations & Project Management at ViaCyte.

Organized by the Alliance for Regenerative Medicine (ARM), the California Institute for Regenerative Medicine (CIRM), and the Sanford Consortium for Regenerative Medicine, the 2013 Stem Cell Meeting on the Mesa is a three-day conference aimed at bringing together senior members of the regenerative medicine industry with the scientific research community to advance stem cell science into cures. The Regen Med Partnering Forum, to be held October 14-15 at the Estancia La Jolla Hotel, is the only partnering meeting organized specifically for the regenerative medicine and advanced therapies industry. The meeting also features a nationally recognized Scientific Symposium, to be held October 16 at the Salk Institute for Biological Studies, showcasing leading academic research in the field of regenerative medicine. Combined, these meetings attract over 800 attendees from around the globe, fostering key partnerships through one-on-one meetings while also highlighting clinical and commercial progress in the field.

The following are specific details regarding ViaCyte’s presentation at the conference:

Event: Regen Med Partnering Forum – 2013 Stem Cell Meeting on the Mesa
Date: Tuesday, October 15, 2013
Time: 3:15 p.m.
Location: Estancia La Jolla Hotel & Spa,
9700 North Torrey Pines Road, La Jolla, CA 92037

A live video webcast of all company presentations will be available at: and will also be published on ARM’s website shortly after the event.

Paul Laikind, Ph.D., ViaCyte’s president and CEO said, “We are excited to review the excellent progress we have made with our VC-01™ combination product since our presentation at last year’s Stem Cell Meeting on the Mesa. Thanks to the hard work of the ViaCyte team and the continuing support of CIRM and JDRF we are on track to initiate a clinical trial in patients with type 1 diabetes in the first half of next year.”